Image 2-XPOVIO (selinexor) - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Image 2-XPOVIO (selinexor)
XPOVIO (selinexor) is the first and only FDA-approved nuclear export inhibitor used for both multiple myeloma and DLBCL. Credit: Karyopharm Therapeutics Inc.